SCHEMBL9288148

SCHEMBL9288148

Cc1ccc(-c2cc(C)cc(F)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.48
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
GRM5 P41594 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NFE2L2 Q16236 1/20 0.38
ALDH1A3 P47895 1/20 0.37
CYP17A1 P05093 2/20 0.36
CYP21A2 P08686 2/20 0.36
CYP11B1 P15538 2/20 0.36
PTGS2 P35354 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265531 0.90 ACHE (0.52) ACHEHDAC3HDAC1HDAC2HDAC8
SCHEMBL20804591 0.90 ACHE (0.52) ACHEHDAC3HDAC1HDAC2HDAC8
SCHEMBL15682003 0.84 ACHE (0.44) ACHEHDAC3HDAC1HDAC2HDAC8
SCHEMBL29763735 0.84 ACHE (0.44) ACHEHDAC3HDAC1HDAC2HDAC8
SCHEMBL25951281 0.82 ACHE (0.50) ACHERXRARXRBTDP1CA1
SCHEMBL1046627 0.82 RXRA (0.56) ACHERXRARXRBTDP1CA1
SCHEMBL16906613 0.81 KIF11 (0.47) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL2692675 0.81 HDAC3 (0.40) ACHEHDAC3HDAC1HDAC2HDAC8
SCHEMBL1622290 0.81 RXRA (0.47) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL20662906 0.80 ACHE (0.42) ACHEHDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20120135997-A1 PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND SHIONOGI & CO., LTD. (JP) 2012-05-31 US disclosed
WO-2011007819-A1 PHARMACEUTICAL PRODUCT CONTAINING LACTAM OR BENZENE SULFONAMIDE COMPOUND 塩野義製薬株式会社 (JP) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135997-A1 PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND BACE1, STS, APP ACHE 252/4885HDAC3 3387/4885HDAC1 3185/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 ACHE 4527/4885HDAC3 82/4885HDAC1 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.